References
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365: 1687–1717
- Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003;349:80–82
- Hryniuk W, Levine MN. Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162–1170
- Farquhar C, Basser R, Marjoribanks J, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2005;3:CD003139
- Rodenhuis S, Bontenbal M, van Hoesel GCM, et al. Efficacy of high-dose alkylating chemotherapy in HER2/ neu-negative breast cancer. Ann Oncol 2006;17:588–596
- Rodenhuis S, Bontenbal M, Beex LVAM, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7–16
- Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumor cells in breast cancer. Br J Cancer 2006;94:8–12
- Hayes DF. Prognostic and predictive factors revisited. Breast 2005;14;493–499
- Nieto Y, Franklin WA, Jones RB, et al. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic pro- genitor cell support. Biol Blood Marrow Transplant 2004;10:415–425
- Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res 2006;12:1019s-1023s. Marrow Transplant